FAST NEWS: Luzhu Biotech repurchases shares
The Latest: Beijing Luzhu Biotechnology Co. Ltd. (2480.HK) announced Monday that it repurchased a combined 1.43 million of the company’s shares on July 12 and 15, after its board authorized…
Loss-making Vaccine Creator Luzhu Aims for IPO Booster Shot
The IPO-bound biotech is still developing its shingles vaccines and other antibody therapies, but the company has spent heavily in recent years on financial productsKey Takeaways:Losses of 1.26 billion yuan…
RELATED ARTICLES
-
Zhengye Biotech’s ‘pet-sized’ IPO leaves plenty of room for more fundraising
ZYBT.US -
Dispute over Covid vaccines casts doubt on Clover Bio recovery
2197.HK
-
WuXi Biologics sells vaccine plant as new U.S. law looms
2269.HK
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
Cancer drug maker Biostar shines on Hong Kong market debut
2563.HK
